nach oben

Erschienen in:

2022 | OriginalPaper | Buchkapitel

5. Grundlagen der medikamentösen Therapie

verfasst von : Fotios Drakopanagiotakis, Andreas Günther

Erschienen in: Seltene Lungenerkrankungen

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

In diesem Kapitel werden verschiedene medikamentöse Verfahren zur Behandlung seltener Lungenerkrankungen mit Fokus auf die interstitiellen Lungenerkrankungen dargestellt. Die vorgeschlagenen Verabreichungswege und Dosierungen sowie die Nebenwirkungen und notwendige Kontrolluntersuchungen werden diskutiert.

Abd Rahman NA, Tett SE et al (2013) Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. Clin Pharmacokinet 52(5):303–331PubMedCrossRef

Alcorn N, Saunders S et al (2009) Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 32(12):1123–1134PubMedCrossRef

Allen J (2006) Acute eosinophilic pneumonia. Semin Respir Crit Care Med 27(2):142–147PubMedCrossRef

Araiza-Casillas R, Cardenas F et al (2004) Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus 13(2):119–124PubMedCrossRef

Barnes PJ (2010) Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 120(2–3):76–85PubMedCrossRef

Baughman RP, Lower EE (2014) Medical therapy of sarcoidosis. Semin Respir Crit Care Med 35(3):391–406PubMedCrossRef

Baughman RP, Judson MA et al (2002) Thalidomide for chronic sarcoidosis. Chest 122(1):227–232PubMedCrossRef

Baughman RP, Nunes H et al (2013) Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J 41(6):1424–1438PubMedCrossRef

von der Beck D, Loh B et al (2014) Antifibrotic treatment. Dtsch Med Wochenschr 139(49):2523–2525PubMedCrossRef

Bharadwaj A, Haroon N (2004) Peripheral neuropathy in patients on leflunomide. Rheumatology (Oxford) 43(7):934CrossRef

Brummaier T, Pohanka E et al (2013) Using cyclophosphamide in inflammatory rheumatic diseases. Eur J Intern Med 24(7):590–596PubMedCrossRef

Carson KR, Evens AM et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113(20):4834–4840PubMedPubMedCentralCrossRef

Cohen SB, Iqbal I (2003) Leflunomide. Int J Clin Pract 57(2):115–120PubMed

Conway R, Low C et al (2014) Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 66(4):803–812CrossRef

Culver DA, Judson MA (2019) New advances in the management of pulmonary sarcoidosis. BMJ 367:l5553. https://doi.org/10.1136/bmj.l5553. Published 2019 Oct 22CrossRefPubMed

Dalrymple JM, Stamp LK et al (2008) Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 58(11):3299–3308PubMedCrossRef

Diamond EL, Subbiah V et al (2018) Vemurafenib for BRAF V600-mutant erdheim-chester disease and langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol 4(3):384–388PubMedCrossRef

Distler O, Highland KB et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380(26):2518–2528PubMedCrossRef

van Ede AE, Laan RF et al (2002) Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 41(6):658–665CrossRef

Egan JJ, Remund KF et al (2008) Sirolimus for lymphangioleiomyomatosis lesions. N Engl J Med 358(18):1963–1964. (author reply 1964)PubMedCrossRef

Faurschou M, Sorensen IJ et al (2008) Malignancies in wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35(1):100–105PubMed

Flaherty KR, Wells AU et al (2019) Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 381(18):1718–1727PubMedCrossRef

Fragoulis GE, Conway R et al (2019) Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature. Rheumatology (Oxford) 58(11):1900–1906CrossRef

Gao Y, Moua T (2020) Treatment of the connective tissue disease-related interstitial lung diseases: a narrative review. Mayo Clin Proc 95(3):554–573PubMedCrossRef

Gearry RB, Barclay ML (2005) Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 20(8):1149–1157PubMedCrossRef

van der Goes MC, Jacobs JW et al (2014) The value of glucocorticoid co-therapy in different rheumatic diseases – positive and adverse effects. Arthritis Res Ther 16(Suppl 2):2CrossRef

Grimminger F, Gunther A, Vancheri C (2015) The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J 45(5):1426–1433PubMedCrossRef

Grobost V, Khouatra C et al (2014) Effectiveness of cladribine therapy in patients with pulmonary langerhans cell histiocytosis. Orphanet J Rare Dis 9(1):191PubMedPubMedCentralCrossRef

Guillevin L (2013) Infections in vasculitis. Best Pract Res Clin Rheumatol 27(1):19–31PubMedCrossRef

Guillevin L, Cordier JF et al (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized wegener’s granulomatosis. Arthritis Rheum 40(12):2187–2198PubMedCrossRef

Guillevin L, Pagnoux C et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371(19):1771–1780PubMedCrossRef

Haroche J, Cohen-Aubart F et al (2015) Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF (V600E)-mutated erdheim-chester disease. J Clin Oncol 33(5):411–418PubMedCrossRef

Horton MR, Santopietro V et al (2012) Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 157(6):398–406PubMedCrossRef

Imokawa S, Colby TV et al (2000) Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 15(2):373–381PubMedCrossRef

Jee AS, Corte TJ (2019) Current and emerging drug therapies for connective tissue disease-interstitial lung disease (CTD-ILD). Drugs 79(14):1511–1528PubMedCrossRef

Jick SS, Lieberman ES et al (2006) Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 55(1):19–26PubMedCrossRef

Judson MA (2012) The treatment of pulmonary sarcoidosis. Respir Med 106(10):1351–1361PubMedCrossRef

Karow T, Lang-Roth R. (2020) Allgemeine und Spezielle Pharmakologie und Toxikologie. Karow, Köln, S 720–730

Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31(6):456–473PubMedCrossRef

King TE Jr, Bradford WZ et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370(22):2083–2092PubMedCrossRef

Kurita T, Yasuda S et al (2015) The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis. Lupus 24(1):3–9PubMedCrossRef

Luqmani RA (2014) State of the art in the treatment of systemic vasculitides. Front Imm 5:471

Maher TM, Corte TJ et al (2020) Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 8(2):147–157PubMedCrossRef

McCormack FX, Inoue Y et al (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364(17):1595–1606PubMedPubMedCentralCrossRef

Mukhtyar C, Guillevin L et al (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68(3):310–317PubMedCrossRef

Nasser M, Traclet J et al (2018) Effect of cladribine therapy on lung cysts in pulmonary langerhans cell histiocytosis. ERJ Open Res 4(1):00089–02017PubMedPubMedCentralCrossRef

Noble PW, Albera C et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377(9779):1760–1769PubMedCrossRef

Ostensen M, Lockshin M et al (2008) Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 47(Suppl 3):iii28–iii31

Pagnoux C, Mahr A et al (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359(26):2790–2803PubMedCrossRef

Pagnoux C, Mahendira D et al (2013) Fertility and pregnancy in vasculitis. Best Pract Res Clin Rheumatol 27(1):79–94PubMedCrossRef

Papiris SA, Tsirigotis P et al (2014) Long-term inhaled granulocyte macrophage-colony-stimulating factor in autoimmune pulmonary alveolar proteinosis: effectiveness, safety, and lowest effective dose. Clin Drug Investig 34(8):553–564PubMedCrossRef

Raj R, Nugent K (2013) Leflunomide-induced interstitial lung disease (a systematic review). Sarcoidosis Vasc Diffuse Lung Dis 30(3):167–176PubMed

Ramiro S, Gaujoux-Viala C et al (2014) Safety of synthetic and biological DMARDS: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73(3):529–535PubMedCrossRef

Relling MV, Schwab M et al (2019) Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther 105(5):1095–1105PubMedCrossRef

Richeldi L, du Bois RM et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2071–2082PubMedCrossRef

Roubille C, Haraoui B (2014) Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 43(5):613–626PubMedCrossRef

Ruiz-Irastorza G, Ramos-Casals M et al (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69(1):20–28PubMedCrossRef

Sahoo DH, Bandyopadhyay D et al (2011) Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 38(5):1145–1150PubMedCrossRef

Schaberg T, Bauer T et al (2012) Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP). Pneumologie 66(3):133–171PubMedCrossRef

Scheffert JL, Raza K (2014) Immunosuppression in lung transplantation. J Thorac Dis 6(8):1039–1053PubMedPubMedCentral

Schiff MH, Jaffe JS et al (2014) Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 73(8):1549–1551PubMedCrossRef

Singh JA, Wells GA et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2:CD008794

Stockley RA, Miravitlles M et al (2013) Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis 8:149PubMedPubMedCentralCrossRef

Strand V, Cohen S et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159(21):2542–2550PubMedCrossRef

Suissa S, Hudson M et al (2006) Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 54(5):1435–1439PubMedCrossRef

Talar-Williams C, Hijazi YM et al (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with wegener granulomatosis. Ann Intern Med 124(5):477–484PubMedCrossRef

Tashkin DP, Roth MD et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708–719PubMedPubMedCentralCrossRef

Tazawa R, Trapnell BC et al (2010) Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 181(12):1345–1354PubMedPubMedCentralCrossRef

Tazawa R, Inoue Y et al (2014) Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy. Chest 145(4):729–737PubMedCrossRef

Teschler H (2015) Long-term experience in the treatment of alpha1-antitrypsin deficiency: 25 years of augmentation therapy. Eur Respir Rev 24(135):46–51PubMedCrossRef

Vargesson N (2015) Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today 105(2):140–156PubMedPubMedCentralCrossRef

van Vollenhoven RF, Emery P et al (2013) Long-term safety of rituximab in rheumatoid arthritis: 9,5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72(9):1496–1502PubMedCrossRef

Vorselaars AD, Wuyts WA et al (2013) Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest 144(3):805–812PubMedCrossRef

Wang K, Zhang H et al (2004) Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc 36(7):2068–2070PubMedCrossRef

Wijsenbeek M, Cottin V (2020) Spectrum of fibrotic lung diseases. N Engl J Med 383(10):958–968PubMedCrossRef

Witt LJ, Demchuk C et al (2016) Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulm Pharmacol Ther 36:46–52PubMedPubMedCentralCrossRef

Wong L, Harper L et al (2015) Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis. Nephrol Dial Transplant 30(Suppl 1):i164–i170PubMed

Xu X, Blinder L et al (1997) In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J Immunol 159(1):167–174PubMed

Yale SH, Limper AH (1996) Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 71(1):5–13PubMedCrossRef

http://dgrh.de

http://dgrh.de/therapieueberwachen.html

http://online.rote-liste.de/

http://www.awmf.org/leitlinien/detail/ll/034-003.html

http://www.ema.europa.eu/ema/

http://www.fda.gov/Drugs/default.htm

https://www.embryotox.de/wirkstoffe.html

Titel: Grundlagen der medikamentösen Therapie
verfasst von: Fotios Drakopanagiotakis
Andreas Günther
Verlag: Springer Berlin Heidelberg
Buch: Seltene Lungenerkrankungen
Print ISBN: 978-3-662-63650-3

Electronic ISBN: 978-3-662-63651-0

Copyright-Jahr: 2022
DOI: https://doi.org/10.1007/978-3-662-63651-0_5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen